Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters
Nadia Soudani(Washington University in St. Louis), Adrianus C. M. Boon, Tamarand L. Darling(Washington University in St. Louis), Ali H. Ellebedy(Washington University in St. Louis), Kuljeet Seehra(Washington University in St. Louis), Traci L. Bricker(Washington University in St. Louis), Nita Patel(Novavax (United States)), Mimi Guebre-Xabier(Novavax (United States)), Gale Smith(Novavax (United States)), Mehul S. Suthar(Emory University), Meredith E. Davis-Gardner(Emory University)
Cited by 7
Related Papers
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization
|Cell Host & Microbe|2021|851